Get the Stockscreener App
3.09
9.91%
-0.34
Pre-market:
3.09
X 4 Pharmaceuticals Inc stock is traded at $3.09, with a volume of 580.78K.
It is down -9.91% in the last 24 hours and down -8.85% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.43
Open:
$3.3
24h Volume:
580.78K
Relative Volume:
0.15
Market Cap:
$69.37M
Revenue:
$32.77M
Net Income/Loss:
$-101.98M
P/E Ratio:
-0.3215
EPS:
-9.6101
Net Cash Flow:
$-112.43M
1W Performance:
-11.21%
1M Performance:
-8.85%
6M Performance:
-51.32%
1Y Performance:
-80.34%
1-Day Range:
$3.07
$3.42
1-Week Range:
$3.07
$3.64
52-Week Range:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.09 | 77.00M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Using data filters to optimize entry into X4 Pharmaceuticals Inc.Analyst Upgrade & Expert Curated Trade Setups - newser.com
Advanced analytics toolkit walkthrough for X4 Pharmaceuticals Inc.July 2025 Action & Community Consensus Picks - newser.com
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Will X4 Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Update & Verified Momentum Watchlists - newser.com
Ranking X4 Pharmaceuticals Inc. among high performing stocks via tools2025 Market Trends & Verified Entry Point Signals - newser.com
Is it time to cut losses on X4 Pharmaceuticals Inc.Weekly Stock Recap & Verified Entry Point Signals - newser.com
Does X4 Pharmaceuticals Inc. show high probability of reboundMarket Activity Report & Reliable Volume Spike Alerts - newser.com
Fierce Biotech Layoff Tracker 2025: Ascidian Tx trims team; Ferring plots 500 layoffs - Fierce Biotech
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by QRG Capital Management Inc. - MarketBeat
How X4 Pharmaceuticals Inc. (48Q0) stock trades pre earningsQuarterly Market Review & Fast Gaining Stock Reports - newser.com
What analysts say about X4 Pharmaceuticals Inc stockTrading Volume Trends & Free Tap Rapid Wealth - earlytimes.in
Is a relief rally coming for X4 Pharmaceuticals Inc. holdersTrade Volume Report & Real-Time Volume Trigger Notifications - newser.com
Analyzing recovery setups for X4 Pharmaceuticals Inc. investors2025 Analyst Calls & Verified Entry Point Detection - newser.com
What does recent volatility data suggest for X4 Pharmaceuticals Inc.Portfolio Value Summary & Advanced Swing Trade Entry Alerts - newser.com
Analyzing X4 Pharmaceuticals Inc. with multi timeframe chartsQuarterly Trade Summary & Fast Entry High Yield Tips - newser.com
X4 Pharmaceuticals Inc 48Q0 Stock Analysis and ForecastPortfolio Allocation Tips & Market Volatility Strategies - earlytimes.in
Finance Watch: Job Cuts At Takeda, Bolt, Innate, X4 As Strategies Shift - insights.citeline.com
How X4 Pharmaceuticals Inc. (48Q0) stock trades after rate cutsIndex Update & Long-Term Growth Plans - newser.com
Will X4 Pharmaceuticals Inc. (48Q0) stock outperform foreign stocks2025 Technical Patterns & Smart Investment Allocation Insights - newser.com
Chart based exit strategy for X4 Pharmaceuticals Inc.Market Sentiment Summary & Long-Term Safe Investment Ideas - newser.com
Is X4 Pharmaceuticals Inc a good long term investmentEmerging Market Stocks & Small Budget Wealth Tips - earlytimes.in
Goldman Sachs Group Inc. Decreases Holdings in X4 Pharmaceuticals, Inc. $XFOR - Defense World
Will X4 Pharmaceuticals Inc. stock benefit from upcoming earnings reportsMarket Weekly Review & Weekly Chart Analysis and Trade Guides - newser.com
Does X4 Pharmaceuticals Inc. (48Q0) stock trade below intrinsic valueJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - newser.com
Detecting support and resistance levels for X4 Pharmaceuticals Inc.Swing Trade & Community Verified Trade Alerts - newser.com
Signal strength of X4 Pharmaceuticals Inc. stock in tech scannersWeekly Stock Report & Free High Return Stock Watch Alerts - newser.com
X4 Pharmaceuticals Inc Stock Analysis and ForecastStock Correlation Metrics & Fast Profit Investment Ideas - earlytimes.in
What drives X4 Pharmaceuticals Inc 48Q0 stock pricePortfolio Risk Assessment & Free ETF and Mutual Fund Comparisons - Early Times
How Analyst Sentiment on X4 Pharmaceuticals Is Shifting After Recapitalization and Leadership Changes - Yahoo Finance
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):